Altimmune touts ‘best-in-class’ lean mass results for weight loss therapy in quest to outdo big time competitors

After a full data analysis, Altimmune is heralding phase 2 obesity data for pemvidutide as “best-in-class” for spurring weight loss while preserving lean mass.

The small biotech is going up against some industry heavyweights with pemvidutide, a GLP-1/glucagon dual receptor agonist currently in mid-phase testing for obesity and several other indications. Altimmune already released data late last year linking the therapy to mean weight loss of 15.6% compared to 2.2% for placebo at week 48.